In NSCLC, a single-center cohort study of non-squamous NSCLC patients with KRAS mutations reported that patients with KRAS G12C mutations had a higher response rate (53.8% versus 8.3%, p = 0.030) and a longer PFS (4.8 months versus 2.1 months, p = 0.028) than those with mutations of other KRAS subtypes [42]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.